Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Fuji
AstraZeneca
Express Scripts
McKinsey
Fish and Richardson
Cipla
US Army
Daiichi Sankyo

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,916,802

« Back to Dashboard

Which drugs does patent 6,916,802 protect, and when does it expire?

Patent 6,916,802 protects CERDELGA and is included in one NDA.

This patent has eleven patent family members in seven countries.
Summary for Patent: 6,916,802
Title: Amino ceramide-like compounds and therapeutic methods of use
Abstract:The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
Inventor(s): Shayman; James A. (Ann Arbor, MI), Harris; David J. (Lexington, MA), Siegel; Craig (Woburn, MA), Nelson; Carol A. (Westford, MA), Copeland; Diane P. (North Billerica, MA)
Assignee: Genzyme Corporation (Cambridge, MA) The Regents of the University of Michigan (Ann Arbor, MI)
Application Number:10/839,497
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 6,916,802

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Genzyme Corp CERDELGA eliglustat tartrate CAPSULE;ORAL 205494-001 Aug 19, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF GAUCHER DISEASE TYPE 1 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,916,802

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,952,370 Amino ceramide-like compounds and therapeutic methods of use ➤ Try a Free Trial
6,030,995 Amino ceramide-like compounds and therapeutic methods of use ➤ Try a Free Trial
6,040,332 Amino ceramide-like compounds and therapeutic methods of use ➤ Try a Free Trial
5,916,911 Amino ceramide--like compounds and therapeutic methods of use ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,916,802

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 5929600 ➤ Try a Free Trial
Australia 774960 ➤ Try a Free Trial
Brazil 0012318 ➤ Try a Free Trial
Canada 2378600 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
US Department of Justice
Covington
AstraZeneca
Cerilliant
Farmers Insurance
Julphar
Express Scripts
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.